Physician profile
Brian Dalton
NPI 1609840396
$583.87
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $28.77 · 2021: $165 · 2022: $93.96 · 2023: $130 · 2024: $16.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $114.14 | 2022-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $74.43 | 2019 | |
| Merck Sharp & Dohme LLC | $41.35 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $40.76 | 2019-2021 | |
| Novo Nordisk INC | $36.91 | 2021 | |
| Astellas Pharma US INC | $34.16 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.30 | 2021 | |
| Sunovion Pharmaceuticals INC. | $31.24 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.55 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $24.98 | 2023 | Farxiga |
| Eisai INC. | $24.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.63 | 2023 | |
| Amgen INC. | $15.29 | 2020 | |
| Amarin Pharma, INC. | $15.26 | 2019 | |
| Dynavax Technologies Corporation | $15.16 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14.59 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $14.01 | 2022 | |
| Pfizer INC. | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.